首页> 外文OA文献 >The Consequence of Drug–Drug Interactions Influencing the Interplay between P-Glycoprotein and Cytochrome P450 3a: An Ex Vivo Study with Rat Precision-Cut Intestinal Slices
【2h】

The Consequence of Drug–Drug Interactions Influencing the Interplay between P-Glycoprotein and Cytochrome P450 3a: An Ex Vivo Study with Rat Precision-Cut Intestinal Slices

机译:影响P-糖蛋白和细胞色素P450 3a之间相互作用的药物相互作用的后果:大鼠精确切肠切片的体内研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

P-glycoprotein (P-gp) and cytochrome P450 3A (CYP3A) are differentially expressed along the intestine and work coordinately to reduce the intracellular concentration of xenobiotics and the absorption of orally taken drugs. Drug–drug interactions (DDIs) based on P-gp/CYP3A interplay are of clinical importance and require preclinical investigation. We investigated the P-gp/Cyp3a interplay and related DDIs with different P-gp inhibitors in the various regions of the rat intestine ex vivo using precision-cut intestinal slices (PCIS) with quinidine (Qi), a dual substrate of P-gp and Cyp3a, as the probe. The results showed that P-gp efflux was the main factor limiting the intracellular Qi content at concentrations below 5 µM, whereas both efflux and metabolism were saturated at [Qi] > 50 µM. The selective P-gp inhibitors CP100356 [N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine] and PSC833 [valspodar, 6-[(2S,4R,6E)-4-methyl-2-(methylamino)-3-oxo-6-octenoic acid]-7-l-valine-cyclosporin A] enhanced the Qi accumulation in slices in line with the different P-gp expression in the intestinal regions and, as a result, also enhanced metabolism in the jejunum and ileum. Dual inhibitors of both P-gp and Cyp3a (verapamil and ketoconazole) increased the concentration of Qi in the jejunum and ileum, but less 3-hydroxy-quinidine was produced due to inhibition of Cyp3a. The results indicate that the P-gp/Cyp3a interplay depends on the concentration of the drug and on the intestinal region under study. Furthermore, due to the P-gp/Cyp3a interplay, DDIs can lead to remarkable changes in the intracellular concentration of both the parent drug and the metabolite, which varies among the intestinal regions and depends on the selectivity of the inhibitors, with potentially important implications for disposition and toxicity of drugs and their metabolites.
机译:P-糖蛋白(P-gp)和细胞色素P450 3A(CYP3A)在肠中差异表达,并协同工作以减少异种生物的细胞内浓度和口服药物的吸收。基于P-gp / CYP3A相互作用的药物相互作用(DDI)具有临床重要性,需要进行临床前研究。我们使用奎尼丁(Qi)(P-gp的双重底物)精密切割的肠片(PCIS),对离体大鼠肠道各个区域中不同P-gp抑制剂的P-gp / Cyp3a相互作用和相关DDI进行了研究和Cyp3a作为探针。结果表明,当浓度低于5 µM时,P-gp外排是限制细胞内Qi含量的主要因素,而当[Qi]> 50 µM时,外排和代谢均达到饱和。选择性P-gp抑制剂CP100356 [N-(3,4-二甲氧基苯乙基)-4-(6,7-二甲氧基-3,4-二氢异喹啉-2 [1H]-基)-6,7-二甲氧基喹唑啉-2-胺]和PSC833 [valspodar,6-[(2S,4R,6E)-4-甲基-2-(甲基氨基)-3-氧代-6-辛烯酸] -7-1-缬氨酸-环孢菌素A]增强了Qi的积累切片与肠道区域中不同的P-gp表达一致,因此也增强了空肠和回肠的新陈代谢。 P-gp和Cyp3a的双重抑制剂(维拉帕米和酮康唑)可增加空肠和回肠中Qi的浓度,但由于抑制了Cyp3a,产生的3-羟基奎尼丁较少。结果表明,P-gp / Cyp3a相互作用取决于药物的浓度和所研究的肠道区域。此外,由于P-gp / Cyp3a的相互作用,DDI会导致母体药物和代谢物的细胞内浓度发生显着变化,这在肠道区域之间会有所不同,并取决于抑制剂的选择性,这可能具有重要的意义。用于药物及其代谢产物的处置和毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号